NOTUSBOREASdupilumabCOPDchronic obstructive pulmonary diseasetype 2 inflammation
…, key and central drivers of type 2 inflammation. In BOREAS and NOTUS, dupilumab reduced exacerbations and improved lung function in …
Entity family
Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.
This institution is selected. Its supporting articles are shown below.
…, key and central drivers of type 2 inflammation. In BOREAS and NOTUS, dupilumab reduced exacerbations and improved lung function in …
…CS and antibiotic use in patients from BOREAS and NOTUS.Methods BOREAS ( NCT03930732) and NOTUS (NCT04456673), phase 3, randomized, pl…
…Purpose In BOREAS and NOTUS, add-on dupilumab reduced moderate-or-severe exacerba…